Liver energy metabolism reprogramming: GLP-1RA reduces hepatic glucose output by decreasing hepatic FFA uptake and the expression of key gluconeogenesis enzymes such as PEPCK and G6Pase, while promoting liver sensitivity to insulin, transforming the liver from an "energy output organ" to an "energy storage organ"
If the remaining Phase 3 readouts hold and the FDA filing proceeds on the projected late- 2026 timeline, retatrutide is positioned to arrive as the unambiguous class leader and the first obesity drug whose efficacy curve starts to genuinely overlap with bariatric surgery
Erectile dysfunction in men taking Ozempic is more commonly related to underlying type 2 diabetes itself, which damages blood vessels and nerves
Though its use hinges on weight-focused outcomes rather than glucose, individuals managing both weight and metabolic health see dual benefits
Maintenance infusion of 250 mg/kg/day (1.2 mM/kg/day)
Day-to-day life produces substances called free radicals that circulate in the body